علاج الثعلبة البقعية مع تساقط شعر فروة الرأس المحدود إلى المعتدل (إصابة 1–49% من فروة الرأس)

References

DOI: 10.1093/bjd/ljae385

• The AA severity definitions used in this living guideline are based primarily on the extent of scalp hair loss, with limited (mild) hair loss representing 1–20% scalp involvement, moderate hair loss representing 21–49% scalp involvement and severe hair loss representing 50–100% scalp involvement.
• Offer* a potent or very potent topical corticosteroid once daily for 3–6 months to people with AA who have scalp hair loss, as the first-line treatment in primary or secondary care.
• Offer* intralesional triamcinolone acetonide (2.5–10 mg mL−1) as a first-line option to adults with limited (mild)-to-moderate AA.
• Consider intralesional triamcinolone acetonide in older children and young people with limited (mild)-to-moderate AA on a case-by-case basis.
• Reassess the use of topical corticosteroids every 3–6 months in people with AA, to assess for improvement and cutaneous side-effects.
• Ultimately, the aim of treatment is complete terminal hair regrowth on the scalp and any other body site affected.